ArticleArthritis research & therapy2017
A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production.
Article in Arthritis research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Family-based genome-wide association study of leprosy in Vietnam.PLoS pathogens · 2020Trial
- The MHC-I-opathy architecture: immunogenetic and biomechanical determinants of disease expression.Zeitschrift fur Rheumatologie · 2026Review
- Monocyte/Macrophage Subsets in the Peripheral Blood, Their Related Cytokines, and Circulating Markers of Fibrosis in Active Takayasu Arteritis and Longitudinal Changes Following Immunosuppressive Therapy.Journal of inflammation research · 2026Article
- Review
- Takayasu arteritis complicated by SAPHO syndrome: A case-based review.Clinical rheumatology · 2025Review
- Ustekinumab merits further exploration in Takayasu arteritis despite a failed randomized controlled trial.Rheumatology advances in practice · 2025Article
- A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu's Arteritis.International journal of molecular sciences · 2024Review
- Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre.RMD open · 2024Article
- Enhanced efficacy of the novel recombinant clone VasSF in a mouse model of antineutrophil cytoplasmic antibody-associated vasculitis.Clinical and experimental immunology · 2024Article
- Animal models for large vessel vasculitis - The unmet need.Rheumatology and immunology research · 2023Review
- Psoriasis and Leprosy: An Arcane Relationship.Journal of inflammation research · 2023Article
- Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis.Diagnostics (Basel, Switzerland) · 2022Review
- An Update on Childhood-Onset Takayasu Arteritis.Frontiers in pediatrics · 2022Review
- Perspectives of JAK Inhibitors for Large Vessel Vasculitis.Frontiers in immunology · 2022Review
- A susceptibility locus in the IL12B but not LILRA3 region is associated with vascular damage in Takayasu arteritis.Scientific reports · 2021Article
- Novel Therapies in Takayasu Arteritis.Frontiers in medicine · 2021Review
- Pathogenesis of liver injury in Takayasu arteritis: advanced understanding leads to new horizons.The Journal of international medical research · 2020Article
- Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis-Similarities and Differences.Current rheumatology reports · 2020Review
- Cellular Signaling Pathways in Medium and Large Vessel Vasculitis.Frontiers in immunology · 2020Review
- Roles of cytotoxic lymphocytes and MIC/LILR families in pathophysiology of Takayasu arteritis.Inflammation and regeneration · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA previous study revealed the association between susceptibility to Takayasu arteritis (TAK) and a single nucleotide polymorphism (SNP) rs6871626 located in IL12B, which encodes interleukin (IL)-12p40, a common component of IL-12p70 and IL-23. We investigated the expression of these cytokines in patients with TAK, stratifying them into those with or without the risk allele at the rs6871626 SNP.
methodsPlasma levels of IL-12p40, IL-12p70, and IL-23 were quantified in 44 patients with TAK and 19 healthy controls (HCs) by enzyme-linked immunosorbent assays. Monocytes were obtained from 20 patients with TAK and 14 HCs, treated with interferon-γ (IFN-γ) and lipopolysaccharide, and then supernatant cytokines were quantified. In addition, the ratio of IFN-γ
resultsThe levels of plasma IL-12p40, plasma IL-12p70, and supernatant IL-12p70 were significantly higher in patients with TAK than in HCs, whereas there were no significant differences in the levels of plasma IL-23, supernatant IL-23, or supernatant IL-12p40. The levels of plasma IL-12p70, supernatant IL-12p40, and supernatant IL-12p70 were significantly higher in patients with the risk allele than in those without. The ratio of CD4
conclusionsThe rs6871626 SNP in IL12B may influence the increased expression of IL-12p40 and IL-12p70. These enhanced cytokines might play roles in the pathophysiology of TAK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.